Hoth Therapeutics is leveraging Lantern Pharma’s breakthrough PredictBBB.ai™ platform, a next-generation artificial intelligence (AI) tool with 94% accuracy in predicting blood-brain barrier permeability.
This adoption positions Hoth at the forefront of AI-driven drug development, reinforcing its commitment to cutting-edge innovation and accelerated therapeutic discovery.
PredictBBB.ai, part of Lantern’s RADR® AI platform, is a game-changing technology designed to eliminate one of the most significant bottlenecks in drug development: determining whether a candidate can cross the blood-brain barrier.
By deploying this AI-driven solution, Hoth expects to streamline candidate selection, reduce development risk, and accelerate timelines toward transformative therapies.
Strategic impact
The ability to cross the blood-brain barrier is a critical success factor for drug candidates. With PredictBBB.ai, Hoth gains access to AI-powered insights that increase precision and reduce uncertainty, potentially creating faster regulatory pathways and higher value inflection points for its pipeline.
